To investigate the characteristics of treatment responders to galantamine.
The purposes of this study are: 1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate AD for 52 weeks. 2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
66
8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
Samsung Medical Center
Seoul, South Korea
Alzheimer's Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K)
Time frame: baseline, 4w, 13w, 26w, 39w, 52w
Seoul-Activities of Daily Living (S-ADL) Seoul-Instrumental Activities of Daily Living (S-IADL) Korean version Neuropsychiatric Inventory (K-NPI)
Time frame: baseline, 4w, 13w, 26w, 39w, 52w
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.